**HEALTH CARE USE & POLICY STUDIES – Patient Registries & Post-Marketing Studies**

**PHP124 REGISTRY OF PATIENT REGISTRIES (RoPR): PURPOSE, DESIGN AND EARLY EXPERIENCE**
Gliklich RE1, Levy D1, Campion DM1, Levy MB1, Karl J1, Berliner E1, Taylor T1, Hossfeld W1, König HH1, Brettschneider C1, Leicht H1, Bickel H1, Dahlhaus A1, Fuchs A1, Genissen J1, Maier W1, Roos-Huizinga D2, Scherer M1, König HH1

1Quintiles Outcome, Cambridge, MA, USA, 2Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA, 3Quintiles, Medford, MA, USA

**OBJECTIVES:** Patient registries are important tools for health care research. The goal of this project, sponsored by the Agency for Healthcare Research and Quality (AHRQ), is to design and implement the Registry of Patient Registries (RoPR), the first searchable, public database specifically designed to provide information on registries. The RoPR is integrated with ClinicalTrials.gov and supports research collaboration, reduces redundancy, and improves transparency in observational clinical research. METHODS: The RoPR consists of a registration system and a public search Web site. The registration system collects over forty data elements which define a registry profile. The search site serves as a central listing of registries and includes options to filter for relevant profiles. RoPR registration is integrated with ClinicalTrials.gov: users registering a study on ClinicalTrials.gov who designate it as a patient registry are presented with a pop-up window displaying the RoPR registration system. Users complete and submit the requested data elements, creating a registry profile in the RoPR that is linked to the ClinicalTrials.gov listing through a unique identifier, the NCT ID. RESULTS: The RoPR was launched on December 1, 2012. As of January 11, 2013, 54 new patient registries are registered on ClinicalTrials.gov. Twelve of these have been fully published in the RoPR, representing 21 different condition areas. Costs are classified as disease/disorder condition (67%), drug (33%), and/or procedure (33%) registries. Reported registry purposes include effectiveness (50%), safety or harm (42%), natural history of disease (42%) and clinical practice assessment (35%). A total of 67% of registry sponsors are open to being contacted for collaboration, data access for investigator or patient participation, or obtaining information requests. CONCLUSIONS: The RoPR is a searchable Web site used by registry sponsors to publish information about registries and by members of the public to search for information about existing registries. Integration with ClinicalTrials.gov presents a user-friendly interface to encourage registration.

**PHP125 POST-MARKETING REQUIREMENTS: AN OVERVIEW OF THE THERAPEUTIC AREAS TARGETED BY THE EMA AND THE FDA**
Caron M1, Emary MP1, Maier W1, Väänänen-Vainio M1

1MAPF Research Trust, Lyon, France, 2Registreet-Mapi, London, UK

**OBJECTIVES:** Post-marketing requirements (PMRs) include studies and clinical trials that sponsors are required to conduct under one or more statutes or regulations. The objective of this research is to identify which therapeutic areas, and within these areas, which therapeutic indications have been subjected to the highest number of PMRs from the Food and Drug Administration (FDA, USA) and the European Medicines Agency (EMA, EU). METHODS: The Post-Marketing Requirements Database was used to explore requirements for post-approval studies published on the websites of the FDA and the EMA since 2005. The search was performed on January 2, 2013. RESULTS: The therapeutic area for which the EMA required the highest number of studies was “factors influencing health status and contact with health services” (n=36) for the indication “prophylaxis of influenza in a pandemic situation” (n=36). Within this indication, ten different study designs were concerned with Pandemrix and Cefpalvax. Studies on products with the highest number of studies requested (n=6 for each product). In comparison, the FDA had requested only 27 studies for the same therapeutic area, and neither Pandemrix nor Cepalvan were approved in the USA. The area for which the FDA required the highest number of studies was “endocrine, nutritional and metabolic diseases” (n=80), and within this area, the more populated indication was “diabetes mellitus”(n=41). Within this indication, Onglyza, Byetta and Victoza were the products with the highest number of studies requested (n=5, 6 respectively). In comparison, the EMA had requested only 14 studies for the same area. Onglyza, Byetta and Victoza were studies requested (n=4, 5, and 6 respectively). In comparison, the EMA had populated indication was “diabetes mellitus”(n=41). Within this indication, nutritional and metabolic diseases” (n=80), and within this area, the more for which the FDA requested the highest number of studies was “endocrine, requirements were also refined through user acceptance testing. Over 110 individuals participated in OMF design activities. RESULTS: Stakeholders identified several challenges to be addressed in the design requirements for the OMF. Stakeholders had different levels of familiarity with the OMF. They want a framework that 1) distinguishes between outcome measures collected on a patient level and those collected or calculated on a population level; 2) describes the frequency or timeframe in which a particular outcome measure is collected; 3) identifies outcome measures that are clinically equivalent to each other and clearly displays this information; and 4) minimizes user burden, in particular participation in the RoPR is currently voluntary. CONCLUSIONS: By using a design that solicits input from a broad range of stakeholders, several challenges were identified in the design of the RoPR prototype, and will require further clarification if the OMF is developed and implemented into a system such as the RoPR.

**HEALTH CARE USE & POLICY STUDIES – Population Health**

**PHP127 RELATIVE IMPACT OF MULTIMORBID CHRONIC CONDITIONS ON HEALTH-RELATED QUALITY OF LIFE MEASURED BY THE EQ-5D**
Brettschneider C1, Leicht H1, Bickel H1, Dahlhaus A1, Fuchs A1, Genissen J1, Maier W1, Roos-Huizinga D2, Scherer M1, König HH1

1University Medical Center Hamburg, Hamburg, Germany, 2Technical University of Munich, Munich, Germany, 3Goethe-University Frankfurt am Main, Frankfurt am Main, Germany, 4University of Düsseldorf Medical Center, Düsseldorf, Germany, 5Jena University Hospital, Jena, Germany, 6University of Bonn, Bonn, Germany, 7University of Leipzig, Leipzig, Germany, 8Medical Faculty Mannheim/Heidelberg University, Mannheim, Germany, 9Hannover Medical School, Hannover, Germany

**OBJECTIVES:** Multimorbidity has a negative impact on health-related quality of life (HRQL). Previous studies included only a limited number of frequent conditions and their combinations. The aim of this study was to analyze the relative impact of a large number of chronic conditions on overall HRQL in multimorbid patients. METHODS: This analysis is based on the MultiCare Cohort study, a multicenter, prospective cohort study of 3189 multimorbid primary care patients between 15 to 85. The impact of 68 conditions was assessed. The severity of the conditions was rated between 0 (insignificant) and 4 (very severe). The EQ-5D, a questionnaire consisting of 5 items (dimensions) and a visual-analogue-scale (EQ VAS) was employed to measure HRQL. Data were analyzed using multiple ordinary least squares regression and multiple logistic regression. RESULTS: Multimorbidity measured by a weighted count score was significantly associated with lower overall HRQL (EQ VAS). Parkinson’s disease had the most pronounced negative effect on overall HRQL (EQ VAS), followed by rheuma, depression, obesity and cardiac insufficiency. With regard to the individual EQ-5D dimensions, depression and obesity affected all five dimensions of the EQ-5D negatively except for the dimension anxiety/depression. Obesity had a positive effect on this dimension. Cardiac insufficiency was associated with three dimensions. The dimensions ‘self-care’ and ‘usual activities’ were most strongly affected by Parkinson’s disease. CONCLUSIONS: The overall HRQL of multimorbid patients decreased with increasing number of conditions. Parkinson’s disease, depression and obesity have the strongest impact on health-related quality of life.

**PHP128 SELF-RA TED HEALTH MEASURES WITH DIFFERENT REFERENCE POINTS AND MORTALITY**
Taylor T1

1USC School of Pharmacy, Los Angeles, CA, USA

**OBJECTIVES:** Self-rated health (SRH) has been shown to be a good predictor of mortality. However, there are many findings of the association between mortality and SRH measures with different reference points (i.e., with respect to either global or peer age group). This study assessed whether SRH measures with different reference frames influence the association of the SRH and mortality in old population. METHODS: We analyzed data from 2000-2005 Medical Expenditure Panel Survey (MEPS) respondents in Panel 5-7, aged 60 or over, linked to the National Death Index (NDI) through 2006. To test whether the SRH measures with different reference points were comparable outcome measures to predict mortality, two SRH measures (global and age-comparative SRHs) were applied separately and concurrently. Cox proportional hazards model was conducted, adjusted for demographic and social characteristics. RESULTS: A total of 4787 respondents were likely to assess their health as excellent or very good on the age-comparative SRH measure than on the global SRH measure (excellent, 14.7% vs 7.6%, very good, 28.6% vs 17.4%). The independent mortality risk for the dimension anxiety/depression were the strongest predictor of mortality. Poor global SRH ratings increased mortality risk by 5.06 times and poor age-comparative SRH rating increased mortality risk by 5.38 times as compared to their respective excellent ratings. When two measures were concurrently analyzed in the relation to mortality risk, both measures significantly predicted mortality and poor global SRH ratings were the strongest predictor of mortality. Hazard ratio = 2.73, 95% CI = [1.694, 4.469]. CONCLUSIONS: Global and age-comparative SRH measures were associated with increased risk of mortality. However, we also found that the global SRH measure tended to have more predictive power than the age-comparative measure. Our findings imply that the different reference points may affect the association between SRH measures and mortality.